M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market Pharmaceutical TechnologyIf approved, Beren's adrabetadex would join Zevra Therapeutics' Miplyffa and IntraBio's Aqneursa on the I-NPC market.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 15, 2026) Pharmaceutical Technology If approved, Beren’s adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Aquipta recommended by NICE for acute migraine treatmentNext: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test Related Stories M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026 M&A / Deals SonoThera bags $125M series B to advance safer gene therapies pharminent June 11, 2026 M&A / Deals Aditxt and Ignite announce merger plans with strategic partner pharminent June 10, 2026
